Press Releases

October 5, 2021

DS BIOPHARMA AND NDSU ENTER LICENSE AGREEMENT TO DEVELOP DALEUTON AS PART OF A NOVEL CANCER TREATMENT TARGETING THE TUMOR MICROENVIRONMENT

Dublin, Ireland and North Dakota, USA, October 5th 2021 DS Biopharma Limited, a developer of bioactive lipid-based pharmaceuticals and the NDSU Research Foundation today announced they […]
March 18, 2021

DS Biopharma and Nuvothera Enter Option and License Agreement for EPADILIN®

• Nuvothera acquires option to licence rights to develop and commercialise DS Biopharma’s EPADILIN® in the US • DS Biopharma becomes an investor in Nuvothera and […]
March 6, 2019

Clinical Study Shows Topical DS107 Prevents Disease Exacerbation in Atopic Dermatitis Patients

Dublin, Ireland, March 06 2019 – DS Biopharma (DS) today announced positive results from a new study where continued treatment with 5% DS107 cream not only […]
November 19, 2018

DS Biopharma announces DS107 patent grant in the US for the treatment of atopic dermatitis

Dublin, Ireland, November 19th 2018 – DS Biopharma (DS), a privately held clinical stage biopharmaceutical company specialising in the development of novel bioactive lipids, today announced […]
October 18, 2018

Oral DS107 found to reverse the molecular signature of moderate to severe atopic dermatitis patients in a phase 2 trial

Dublin, Ireland, October 18th 2018 – DS Biopharma (DS), a privately held biopharmaceutical company, today announced that oral treatment with DS107 reversed the molecular signature of […]
October 3, 2018

DS Biopharma announces positive top-line phase 2b trial results for DS107 as a topical treatment for mild to moderate atopic dermatitis

DS Biopharma announces positive top-line phase 2b trial results for DS107 as a topical treatment for mild to moderate atopic dermatitis Dublin, Ireland, October 3rd 2018 […]